Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors. FoundationOne CDx is intended for use by health care professionals to help inform cancer treatment management in accordance with professional guidelines for patients …
Tag Archives: precision medicine
December, 2017
August, 2017
-
21 August
Champions Oncology Enters Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of PDX Models
HACKENSACK, N.J., Aug. 21, 2017 /PRNewswire/ — Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These …
-
4 August
New Research Shows the Power of Radiomics to Improve Precision Medicine
TAMPA, Fla. (Aug. 3, 2017) – Precision medicine has become the leading innovation of cancer treatment. Patients are routinely treated with drugs that are designed to target specific tumors and molecules. Despite the progress that has been made in targeted cancer therapies, the path has been slow and scientists have …
June, 2017
-
29 June
Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders
LOWELL, Mass., June 29, 2017 /PRNewswire/ — Alcyone Lifesciences, Inc., a leader in precision advanced central nervous system (CNS) delivery systems announced that it has entered into a feasibility study agreement with Pfizer Inc. (NYSE: PFE) in the area of genetic therapy targeting rare and orphan neurological disorders. The feasibility …
-
19 June
New Three-In-One Blood Test Opens Door to Precision Medicine for Prostate Cancer
Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes. By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to …
-
8 June
ASCO and Foundation Medicine Collaborate to Identify Participants for the Targeted Agent & Profiling Utilization Study
ALEXANDRIA, Va. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–The American Society of Clinical Oncology, Inc. (ASCO) and Foundation Medicine (NASDAQ: FMI) today announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s …
-
1 June
Philips and MSK Enter Partnership on Genome Analytics for Prostate Cancer Precision Medicine
AMSTERDAM and NEW YORK, June 1, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, today announced a research collaboration to help improve the understanding of pancreatic cancer and …
May, 2017
-
16 May
Alexion and Rady Children’s Institute for Genomic Medicine Partner to Speed Diagnosis of Rare Genetic Disorders in Newborns
SAN DIEGO & NEW HAVEN, Conn.–(BUSINESS WIRE)–The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities …
April, 2017
-
21 April
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …
March, 2017
-
31 March
Bristol-Myers to Leverage Foundation Medicine’s Platform to Identify Predictive Biomarkers
NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating Bristol-Myers …